

Amendments to the Claims:

The following listing of claims will replace all prior versions, and listings, of claims in the application:

1. (Original) A monoclonal antibody which specifically recognizes A β 11-x peptides.
2. (Original) A monoclonal antibody according to claim 1 which specifically recognizes the first 5 to 7 human amino acids of the β -secretase₁₁ cleavage site, *i.e.* Seq Id No.:1 and Seq Id No.:2 or the first 5 to 7 mouse amino acids of the β -secretase₁₁ cleavage site, *i.e.* Seq Id No.:3 and Seq Id No.:4, as immunogens.
3. (Currently Amended) An antibody as claimed in ~~claims 1 or 2~~ claim 1 that is detectably labeled.
4. (Original) An antibody as claimed in claim 3 wherein the detectable label is a radiolabel, an enzyme label, a luminescent label or a fluorescent label.
5. (Currently Amended) An antibody as claimed in ~~any one of claims 1 to 4~~ claim 1 that is immobilized on a carrier.
6. (Currently Amended) A monoclonal antibody according to ~~any one of claims 1 to 5;~~ claim 1, expressed by the hybridoma cells J&JPRD/hA β 11/1 and J&JPRD/hA β 11/2 deposited at the Belgian coordinated collection of microorganisms on August 19, 2002 with accessionnumbers LMBP 5896CB and LMBP 5897CB respectively.
7. (Original) The hybridoma cells J&JPRD/hA β 11/1 and J&JPRD/hA β 11/2 deposited at the Belgian coordinated collection of microorganisms on August 19, 2002 with accessionnumbers LMBP 5896CB and LMBP 5897CB respectively.

8. (Currently Amended) An immunoassay method for the determination or detection of A β 11-x peptides in a sample, the method comprising contacting the sample with an antibody to A β 11-x peptides as claimed in ~~any one of claims 1 to 3~~ claim 1 and determining whether an immune complex is formed between the antibody and the A β 11-x peptide.
9. (Currently Amended) A method for the detection of the presence of A β 11-x peptides in a tissue sample, the method comprising:
- obtaining a tissue sample from the body of a subject;
 - contacting the tissue sample with an imaging effective amount of a detectably labeled antibody as claimed in ~~claims 3 or 4~~ claim 3; and
 - detecting the label to establish the presence of A β 11-x peptides in the tissue sample.
10. (Currently Amended) A method ~~according to claim 9~~ for the detection of the presence of A β 11-x peptides in a tissue sample, the method comprising:
- obtaining a tissue sample from the body of a subject;
 - contacting the tissue sample with an imaging effective amount of a detectably labeled, monoclonal antibody which specifically recognizes A β 11-x peptides; and
 - detecting the label to establish the presence of A β 11-x peptides in the tissue sample;
- wherein the antibody that is detectably labeled, is expressed by at least one of the hybridoma cells as claimed in claim 7.
11. (Currently Amended) A method for the detection of the presence of A β 11-x peptides in a body fluid sample, the method comprising:
- obtaining a body fluid sample from the body of a subject;

contacting the body fluid sample with an imaging effective amount of a detectably labeled antibody as claimed in claim 3; ~~or 4;~~ and

detecting the label to establish the presence of A β 11-x peptides in the body fluid sample.

12. Canceled.
13. (Currently Amended) The use of a monoclonal antibody as ~~claimed in any one of claims 1 to 6~~ which specifically recognizes A β 11-x peptides in a method according to ~~claims 9 or 10~~ claim 9.
14. (Currently Amended) The use of an antibody as claimed in ~~any of claims 1 to 6~~ claim 1 for the diagnosis of β -amyloid-related diseases.
15. (Currently Amended) A diagnostic composition comprising an antibody as claimed in ~~any of claims 1 to 6~~ claim 1 and a pharmaceutically acceptable carrier.
16. (Currently Amended) An immunoassay kit for the diagnosis of β -amyloid-related diseases comprising an antibody as claimed in ~~any of claims 2 to 5~~ claim 2 and carrier means for the antibody.